On October 20, 2025 GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical stage biotechnology company focused on the development of glycan-directed cancer immunotherapies, reported that an abstract describing preclinical research on its first-in-class antibody-drug conjugate (ADC), GNX1021, has been accepted for presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), taking place October 22–26, 2025, in Boston, Massachusetts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstract, titled "Targeting branched Lewis B/Y glycans with GNX1021: A novel ADC approach for HER2-low gastric cancer," describes preclinical work characterizing GNX1021’s novel glycan-targeting mechanism. GNX1021 is engineered to recognize branched Lewis B/Y, a tumor-associated glycan highly expressed in gastric and other epithelial tumors but with limited expression in healthy tissue, potentially enabling a new level of tumor selectivity.
GlycoNex anticipates submitting an Investigational New Drug (IND) application in the first quarter of 2026 for a first-in-human clinical trial of GNX1021. The program builds on GlycoNex’s proprietary GlycoSH antibody bank and extensive expertise in glycan-directed antibody and ADC development.
Presentation Details:
Event:
American Association for Cancer Research (AACR) (Free AACR Whitepaper) NCI-EORTC
International Conference on Molecular Targets and Cancer Therapeutics
2025
Session:
Poster Session B
Abstract Title:
Targeting branched Lewis B/Y glycans with GNX1021: A novel ADC
approach for HER2-low gastric cancer
Date and Time:
Friday, October 24, 12:30-4:00 pm
Location:
Hynes Convention Center, Boston; Level 2, Exhibit Hall D
(Press release, GlycoNet, OCT 20, 2025, View Source [SID1234656835])